EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Development of a Humanized Antibody Targeting Extracellular HSP90α to Suppress Endothelial-Mesenchymal Transition-Enhanced Tumor Growth of Pancreatic Adenocarcinoma Cells

Chi-Shuan Fan, Hui-Chen Hung, Chia-Chi Chen, Li-Li Chen, Yi-Yu Ke, Teng-Kuang Yeh, Chin-Ting Huang, Teng-Yuan Chang, Kuei-Jung Yen, Chung-Hsing Chen iD, Kee Voon Chua, John Tsu-An Hsu und 1 weitere

Cells · 2024

DOI: 10.3390/cells13131146 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cells, 2024. Verfasst von Chi-Shuan Fan und 12 weiteren Autor:innen. Beteiligte Einrichtung: National Institute of Cancer Research, National Health Research Institutes, Miaoli 35053, Taiwan. Hauptthemen laut MEDLINE: HSP90 Heat-Shock Proteins, Pancreatic Neoplasms, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Health Research Institutes, National Science and Technology Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Extracellular HSP90α (eHSP90α) is a promoter of tumor development and malignant progression. Patients with malignancies, including pancreatic ductal adenocarcinoma (PDAC), have generally shown 5~10-fold increases in serum/plasma eHSP90α levels. In this study, we developed a humanized antibody HH01 to target eHSP90α and evaluated its anticancer efficacy. HH01, with novel complementarity-determining regions, exhibits high binding affinity toward HSP90α. It recognizes HSP90α epitope sites 235AEEKEDKEEE244 and 251ESEDKPEIED260, with critical amino acid residues E237, E239, D240, K241, E253, and K255. HH01 effectively suppressed eHSP90α-induced invasive and spheroid-forming activities of colorectal cancer and PDAC cell lines by blocking eHSP90α’s ligation with the cell-surface receptor CD91. In mouse models, HH01 potently inhibited the tumor growth of PDAC cell grafts/xenografts promoted by endothelial-mesenchymal transition-derived cancer-associated fibroblasts while also reducing serum eHSP90α levels, reflecting its anticancer efficacy. HH01 also modulated tumor immunity by reducing M2 macrophages and reinvigorating immune T-cells. Additionally, HH01 showed low aggregation propensity, high water solubility, and a half-life time of >18 days in mouse blood. It was not cytotoxic to retinal pigmented epithelial cells and showed no obvious toxicity in mouse organs. Our data suggest that targeting eHSP90α with HH01 antibody can be a promising novel strategy for PDAC therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HSP90 Heat-Shock ProteinsPancreatic NeoplasmsAntibodies, Monoclonal, HumanizedHumansAnimalsMiceCell Line, TumorCell ProliferationEpithelial-Mesenchymal TransitionXenograft Model Antitumor AssaysAdenocarcinomaCarcinoma, Pancreatic DuctalEndothelial-Mesenchymal Transition

Stichwörter der Autor:innen

CD91M2 macrophageendothelial-mesenchymal transitionextracellular HSP90αtumor immunity

Substanzen

HSP90 Heat-Shock ProteinsAntibodies, Monoclonal, HumanizedHSP90AA2P protein, human

Autor:innen und Institutionen

  • National Institute of Cancer Research, National Health Research Institutes, Miaoli 35053, Taiwan.
  • Institute of Biotechnology and Pharmaceutical Research, National Health Research Institutes, Miaoli 35053, Taiwan.
  • Anbogen Therapeutics, Taipei 11571, Taiwan.
  • Department of Biochemistry, School of Medicine, Kaohsiung Medical University, Kaohsiung 80708, Taiwan.
  • Doctoral Program in Tissue Engineering and Regenerative Medicine, Biotechnology Center, National Chung Hsing University, Taichung 40227, Taiwan.

ORCID-Profile: Chung-Hsing Chen, Tze-Sing Huang

Förderung

  • National Health Research Institutes
  • National Science and Technology Council

Zitieren

APA

Fan, C. S., Hung, H. C., Chen, C. C., Chen, L. L., Ke, Y. Y., Yeh, T. K., Huang, C. T., Chang, T. Y., Yen, K. J., Chen, C. H., Chua, K. V., Hsu, J. T., & Huang, T. S. (2024). Development of a Humanized Antibody Targeting Extracellular HSP90α to Suppress Endothelial-Mesenchymal Transition-Enhanced Tumor Growth of Pancreatic Adenocarcinoma Cells. Cells. https://doi.org/10.3390/cells13131146

Vancouver

Fan CS, Hung HC, Chen CC, Chen LL, Ke YY, Yeh TK, et al. Development of a Humanized Antibody Targeting Extracellular HSP90α to Suppress Endothelial-Mesenchymal Transition-Enhanced Tumor Growth of Pancreatic Adenocarcinoma Cells. Cells. 2024. doi:10.3390/cells13131146

BibTeX
@article{Fan2024,
  author = {Fan, Chi-Shuan and Hung, Hui-Chen and Chen, Chia-Chi and Chen, Li-Li and Ke, Yi-Yu and Yeh, Teng-Kuang and Huang, Chin-Ting and Chang, Teng-Yuan and Yen, Kuei-Jung and Chen, Chung-Hsing and Chua, Kee Voon and Hsu, John Tsu-An and Huang, Tze-Sing},
  title = {Development of a Humanized Antibody Targeting Extracellular HSP90α to Suppress Endothelial-Mesenchymal Transition-Enhanced Tumor Growth of Pancreatic Adenocarcinoma Cells},
  journal = {Cells},
  year = {2024},
  doi = {10.3390/cells13131146}
}
Kostenlos starten →